Testing positive for SARS-CoV-2 is associated with an increased risk for incident type 1 diabetes, but this is restricted to the first 30 days post-infection and may be explained by increased testing frequency around the time of diabetes diagnosis, researchers report.

Read this Hot Topic Review to catch up on the latest research into the risks and benefits of fasting for people with diabetes.

The pilot MIDDAS study suggests that a 2-day per week very-low-calorie diet could be a viable alternative to a continuous diet for people with type 2 diabetes who struggle with this approach.

Insulin-naïve people with type 2 diabetes initiating the second-generation basal insulins glargine 300 or degludec 100 experience similar improvements in glycated hemoglobin levels, show data from the real-world RESTORE-2 study.

A large number of people diagnosed with type 2 diabetes achieve intermediate or even normal glucose levels within the following few years, with regression to the mean accounting for more than half of these remissions, research suggests.

Obesity is a significant predictor of poor COVID-19 outcomes in patients who also have type 2 diabetes, but only in those up to the age of 75 years, report French researchers.

Starting sotagliflozin in people with type 2 diabetes during or shortly after hospitalization for heart failure significantly reduces their risk for further cardiovascular events over the following months, show the results of the SOLOIST-WHF trial.

Switching to fast-acting insulin aspart significantly improves glycemic control and time in glucose target range in people with type 1 diabetes using continuous glucose monitoring, data from the real-world GoBolus study show.

Cardiovascular event rates do not differ significantly among people with type 2 diabetes treated with linagliptin or glimepiride regardless of age, but those who receive linagliptin have lower risks for falls and hypoglycemia, CAROLINA trial data show.

Add-on treatment with the SGLT1 and 2 inhibitor sotagliflozin may reduce cardiovascular risk among patients with type 2 diabetes and chronic kidney disease, suggest findings from the SCORED trial published in The New England Journal of Medicine .

The GLIMLINA results have also been published in Diabetes Care . medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group EASD virtual meeting; 21–25 September 2020 Diabetes Care 2020; 43: 2025–2033

Two prospective studies published in The BMJ add to the evidence that higher intake of fruit, vegetables, and wholegrain foods is associated with a decreased risk for developing type 2 diabetes.

Getting too little or too much sleep is associated with higher death rates among adults with type 2 diabetes when compared to individuals without diabetes, according to data from a large prospective cohort study.

Dulaglutide is associated with better treatment persistence and lower rates of treatment modification versus other glucagon-like peptide‑1 receptor agonists in people with type 2 diabetes, suggests a study of Swedish health registries.

A small randomized crossover trial indicates that treatment with empagliflozin in people with type 2 diabetes and heart failure already using a loop diuretic results in increased urine output without sodium loss.

The latest research supports uncontrolled blood glucose as a risk factor for poor COVID-19 outcomes in patients without diabetes, and insulin use as a risk marker in those with diabetes.

S everal therapies aimed at slowing the progression of early type 1 diabetes show promise in research presented at the virtual 80th ADA Scientific Sessions.

Continuous glucose monitoring is well accepted and reduces time in hypoglycemia among older individuals with type 1 diabetes, report researchers in JAMA .

An observational study suggests that prior metformin use may offer a protective effect against COVID-19 mortality in people with type 2 diabetes, but only for women.